The NADINA trial of neoadjuvant ipi/nivo vs adjuvant nivo in melanoma is a plenary #ASCO24 . Shorter periods of therapy in responders (neoadjuvant alone) is an important question. Neoadjuvant nivo didn’t work in RCC (PROSPER). PACIFIC2 struggled in lung ascopubs.org/doi/10.1200/JC…

There is nowhere safe in #Gaza , and there is nowhere people can access the basics needed to survive. Forcibly displacing people from #Rafah will likely seal the fate of many children. We call on all States to act now to protect civilians and prevent atrocity crimes in Rafah.

Sumanta K. Pal, MD, FASCO John Haanen The Netherlands Cancer Institute Society for Immunotherapy of Cancer Toni Choueiri, MD Myriam Chalabi Neeraj Agarwal, MD, FASCO MarleenKokLab Ben Tran Sapna Patel Agree 1000% on John Haanen The Netherlands Cancer Institute . The work that he had done, the collaborations. Appropriate next step for this friend, colleague, mentor.

Sumanta K. Pal, MD, FASCO John Haanen The Netherlands Cancer Institute Society for Immunotherapy of Cancer Myriam Chalabi Neeraj Agarwal, MD, FASCO MarleenKokLab Ben Tran Omid Hamid MD Sapna Patel In full agreement with Sumanta K. Pal, MD, FASCO ! John is a selfless mentor and a pioneer in translational and clinical science in cancer immunotherapy Myriam Chalabi The Netherlands Cancer Institute

Terrific list. I’ve worked closely with John Haanen The Netherlands Cancer Institute & have found him to be a generous & thoughtful collaborator! He would be a terrific leader for Society for Immunotherapy of Cancer! Toni Choueiri, MD Myriam Chalabi Neeraj Agarwal, MD, FASCO MarleenKokLab Ben Tran Omid Hamid MD Sapna Patel

May 7th. #ESMO24 deadline! Looking forward to reading all the exciting #CRC /lower GI abstracts! And submitting some…! Jenny Seligmann as CRC track chair 💪

#ESMOGI24 (26-29 June, 📍Munich): the deadline for late registration is approaching on 👉May 29. Secure your place today to ensure access to cutting-edge presentations, interactive sessions, and dynamic discussions led by global leaders in the field.
🔗ow.ly/IgLF50RiaTw

Very happy to host Ulrike Harjes Nature Medicine at the The Netherlands Cancer Institute and discuss all the exciting science that is ongoing and upcoming!

⭐️One of the greatest advantages of in person scientific meetings is to find camaraderie & partnerships with amazing oncology leaders from all over the world. One mission = Eradicate cancer ESMO - Eur. Oncology Toni Choueiri, MD Myriam Chalabi MarleenKokLab OncoAlert OncLive.com OncoDaily cc Tony Mok

Very happy to be part of this group led by Myriam Chalabi and Toni Choueiri, MD . Everyone, prepare to submit your abstracts about AI in oncology to #ESMO25 in Berlin ☺️🇪🇺

Our Editor Spotlight this week is John B. Haanen, MD PhD (John Haanen), ESMO Open Editor for Immunotherapy. Dr. Haanen’s work focuses on the development of innovative immunotherapies, including antibodies, vaccines, gene therapies and cellular therapies. esmo.org/about-esmo/bio…

🧪 All you need to know about the state of play of cell therapy in solid cancers - Fantastic tour de force talk by Sebastian Klobuch AACR #AACR24 on advances in TILs & modified-TCR therapies.

Also check out the latest review by Sebastian Klobuch & colleagues The Netherlands Cancer Institute 👇
nature.com/articles/s4157…

Call for Abstracts! Showcase your research at #ESMOGI24 , 26-29 June, Munich, Germany, and online! Submit your abstract by 9 April 2024 to join leading experts in advancing GI oncology. Don't miss this opportunity to make an impact!

Getting ready to submit for #ESMOGI24 ! Deadline = April 9th. See you in Munich!

As we celebrate Harvest Day, we are continuously grateful for the harvest of each year🌾!

It is an extreme honor and pleasure to co-chair OncoParty 2024: Summer is Coming (by OncoDaily) Hosting Committee with a great friend and incredible physician-scientist Yelena Y. Janjigian MD! May 31, 8:30pm, Chicago! More details soon!
#OncoParty #OncoParty 24 #OncoDaily #ASCO

Celbioloog René Medema geridderd vanwege zijn bijdrage aan kankeronderzoek en kankerzorg parool.nl/nederland/celb…